Geranylgeraniol suppresses the viability of human DU145 prostate carcinoma cells and the level of HMG CoA reductase. (November 2013)

• Record Type: Journal Article
• Authors: Fernandes, Nicolle V; Yeganehjoo, Hoda; Katuru, Rajasekhar; DeBose-Boyd, Russell A; Morris, Lindsey L; Michon, Renee; Yu, Zhi-Ling; Mo, Huanbiao
• Is Part Of: Experimental biology and medicine. Volume 238:Number 11(2013)
• Page Start: 1265
• Page End: 1274
• Publication Date: 2013-11
• Subjects: Geranylgeraniol -- prostate carcinoma -- HMG CoA reductase -- mevalonate -- cell cycle -- apoptosis; Physiology -- Periodicals; Biology, Experimental -- Periodicals; Medicine, Experimental -- Periodicals; 610.72
• DOI: 10.1177/1535370213492693
• Languages: English
• ISSNs: 1535-3702

Abstract

The rate-limiting enzyme of the mevalonate pathway, 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, provides essential intermediates for the prenylation of nuclear lamins and Ras and dolichol-mediated glycosylation of growth factor receptors. The diterpene geranylgeraniol downregulates the level of HMG CoA reductase and suppresses the growth of human liver, lung, ovary, pancreas, colon, stomach, and blood tumors. We evaluated the growth-suppressive activity of geranylgeraniol in human prostate carcinoma cells. Geranylgeraniol induced dose-dependent suppression of the viability of human DU145 prostate carcinoma cells (IC50 = 80 ± 18 µmol/L, n = 5) following 72-h incubations in 96-well plates. Cell cycle was arrested at the G1 phase with a concomitant decrease in cyclin D1 protein. Geranylgeraniol-induced apoptosis was detected by flow cytometric analysis, fluorescence microscopy following acridine orange and ethidium bromide dual staining, and caspase-3 activation. Geranylgeraniol-induced viability suppression was accompanied by concentration-dependent decrease in the level of HMG CoA reductase protein. As a nonsterol molecule that downregulates HMG CoA reductase in the presence of sterols, geranylgeraniol may have potential in the chemoprevention and/or therapy of human prostate cancer.